News | June 24, 2016

CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing Funding to Support the Development of its CRISPR/Cas9 Gene-Editing Platform and Programs BASEL, Switzerland and Cambridge, Massachusetts – CRISPR Therapeutics, a biopharmaceutical company focused...

News | June 20, 2016

Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Patients with Relapsed/Refractory B-cell Lymphoma Company Focused on Initiating Multi-center, Phase 1 Trial in Second Half of 2016 – CAMBRIDGE, MA, June 20, 2016 – a...

News | June 20, 2016

Kit Check Closes $15 Million Series C Round Baxter Ventures Leads Round; Black Granite Capital, Kaiser Permanente Ventures, Rex Health Ventures, New Leaf Venture Partners, Easton Capital Management, LionBird and Sands Capital Ventures Participate Kit...

News | June 9, 2016

Merck to Acquire Afferent Pharmaceuticals KENILWORTH, N.J. & SAN MATEO, Calif., June 9, 2016 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive...

News | June 7, 2016

Arvinas Publishes First Peer-Reviewed, In Vivo Data from its Proprietary PROTAC Technology PROTACs demonstrated to degrade oncology target BET proteins, causing cell death in prostate cancer cells and tumor growth inhibition or regression in mouse models of prostate...
ut dictum at ante. id Aliquam quis, ut